Neurona Therapeutics

Neurona Therapeutics develops regenerative cell therapies for neurological issues affecting an individual’s nervous system such as epilepsy and Alzheimer’s. The company’s therapeutics use inhibitory neurons, myelinating glial cells, and gene-edited cells in its therapeutics. Neurona’s regenerative therapies, once administered, permanently integrate into a patient’s neural circuit, replacing affected cells and rebalancing dysregulated electrical activity in order to repair a patient’s nervous system.

As of August 2023, the company had disclosed two potential inhibitory neuron treatment candidates, one for the treatment of epilepsy, and the other for Alzheimer’s. The treatments were in Phase I and II of clinical testing and preclinical evaluation stages respectively. The company noted that its inhibitory neuron therapy for epilepsy is designated as first-in-class. Additionally, the company was developing therapeutics based on myelinating glial cells and gene-edited cells, which have undisclosed applications, and were in preclinical evaluation and candidate ID stages, respectively.